Potential vaccine for most deadly form of cancer begins human trials

Novel trials for a vaccine against triple negative breast cancer have gone underway.


Getty Images

This vaccine can possibly alleviate potential risks for other types of cancer.

Jasmin Parrado, Staff Writer

A first of its kind is in the works: The Cleveland Clinic and Anixa Biosciences, Inc. have teamed up to launch a trial study of what could be a substantial preventative measure against breast cancer—more specifically, triple negative breast cancer (TNBC), which is also commonly known as the most dangerous form thereof.


TNBC takes up only about 10-15% of all breast cancers—but don’t let that fool you. Its low survival rate and difficult implications mark its severity; this is due to the impossibility of utilizing hormonal therapy to treat the illness at hand. With no characteristics or factors in its biological premise prompting a response to hormone treatment, it is difficult to address and treat with haste and therefore leaves patients with no other choice than to undergo a mastectomy (surgical removal of the entire breast).


With this study, researchers hope to determine the proper dosage of the developed concentration to achieve optimal effect in creating an option that does not require such risky measures.


When in effect, the phase one trial will assess survivors of TNBC that treated it in its earlier stages, and, despite their current remission, suffer an incredibly high risk of developing it once more. They will be provided with three injections, two weeks apart each, for accurate assessment of the vaccine’s effectiveness.


What’s crucial about this particular treatment study lies in the timeframe in which the vaccine is set; instead of targeting the disease after it has already made its way throughout the body, it initially presents itself as a preventative course of treatment before any sort of cancerous development can occur. Like most known childhood vaccinations, this one takes the element of exposure and immunity to combat the threat of TNBC.


The very fact that the advances of technology and medical caliber have allowed for researchers to hypothesize the possible prevention of an otherwise hardly controllable disease is already an incredible step up from the various courses of therapy and trivial prospects for such a tricky form of it.


With the arrival of trial results, researchers will find the answers to their very questions of what dosage is best, and with the matter of TNBC under subject, such answers may serve an essential medical breakthrough.